Heninger Garrison Davis is one of the leading law firms in the country pursuing claims for victims of heart attacks and strokes caused by Vioxx, a prescription pain reliever.  On November 28, 2006, our attorneys made opening arguments in the first trial over Vioxx in the Southeast.  The lawsuit was brought on behalf of our client Gary Albright.  Steve Heninger, Lewis Garrison, and Tim Davis are our lead attorneys in the case.

Merck & Co., the pharmaceutical giant, launched Vioxx in 1999. The drug was withdrawn from the market on September 30, 2004, following reports that linked it with increased risks of heart attacks and strokes.

As early as 1996, during clinical trials, Merck became aware that Vioxx posed an increased risk of blood clots which could cause heart attacks and strokes. Later, Merck sponsored a study designed to test the gastrointestinal safety of Vioxx when compared to naproxen, another pain reliever. That study showed an increased risk of cardiovascular events in patients taking Vioxx, versus patients on naproxen.  Merck thereafter initiated a campaign to suppress awareness of the cardiovascular risks exposed by the study.

Our Firm’s Role in Vioxx Litigation

Our attorneys Lewis Garrison and Bill Bross are on several committees with other plaintiffs' attorneys who are guiding the consolidated federal cases against Merck. This consolidated litigation is based in New Orleans. The first federal trial against Merck was held in 2005 in Houston (relocation due to Hurricane Katrina).  Trials of our clients’ claims against Merck began in state court late in 2006.  These trials are some of the earliest in the nation over Vioxx.

For more information concerning the Vioxx litigation, please fill out and submit our confidential questionnaire, or contact us by email at wlbross@hgdlawfirm.com, or phone Heninger Garrison Davis at 1-800-241-9779.  Click here for our confidential questionnaire